Stephens initiated coverage on Alphatec Holdings (NASDAQ:ATEC) with an Overweight rating. The investment firm set a price target of $15.00 per share.
Stephens identifies Alphatec as a disruptor in the historically stagnant spine surgery market. The company’s strategy integrates implants and access systems into standardized surgical procedures. This approach aims to improve clinical outcomes by combining multiple proprietary technologies.
Analysts believe Alphatec remains in the early stages of market penetration. The firm sees a substantial runway for continued growth and market share gains.
Alphatec shares have underperformed year-to-date due to concerns regarding surgical growth durability. The stock currently trades significantly below its 52-week high. Stephens expects the new rating to serve as a positive catalyst for the share price.